| Home | E-Submission | Sitemap | Contact Us |  
Korean J Intern Med > Volume 31(4); 2016 > Article
Kang, Kim, Lee, Park, Kim, and Shin: Tumor necrosis factor α is a risk factor for infection in peritoneal dialysis patients



It has been shown that circulating tumor necrosis factor α (TNF-α) is elevated in end stage renal disease patients; however, the relationship between TNF-α and the development of infection in these patients is unknown. In this study, we investigated the association of plasma TNF-α and interleukin 6 (IL-6) with infection in peritoneal dialysis (PD) patients. We also evaluated the association of their plasma levels with the production by peripheral blood mononuclear cells (PBMC), and with various clinical parameters.


We enrolled 32 patients on maintenance PD and 10 healthy controls. Plasma and PBMC were isolated from blood. PBMC were stimulated with lipopolysaccharide in vitro.


Mean follow-up duration was 775 days. Six patients developed organ infections (five pneumonia and one liver abscess), and six patients developed PD peritonitis and eight developed exit site infection. Plasma TNF-α and IL-6 levels were significantly elevated in organ infections but not in peritonitis or in exit site infection. Plasma TNF-α was the only significant risk factor for organ infections and pneumonia in multivariate regression analysis. Patients with high plasma TNF-α levels showed a significantly greater cumulative hazard rate for organ infections compared to those with low TNF-α levels. Plasma TNF-α levels correlated with TNF-α production by PBMC and showed an inverse association with Kt/V.


This is the first study showing that plasma TNF-α is a significant risk factor for infection in PD patients.


Tumor necrosis factor α (TNF-α) is a pro-inflammatory polypeptide cytokine implicated in various diseases, and circulating TNF-α was found to be elevated in uremic patients [1]. Interleukin 6 (IL-6) is another important pro-inflammatory cytokine and elevated circulating IL-6 has been associated with cardiovascular diseases and mortality in end stage renal disease (ESRD) patients [2-5]. As for the causes of increased TNF-α and IL-6 in uremic patients, decreased clearance by kidney [6,7], and enhanced secretion by circulating mononuclear cells [8,9] have been suggested. Though the data are conflicting, TNF-α in ESRD patients has been implicated in malnutrition [1,10] cardiovascular diseases [3,11] and erythropoietin resistance [12], which have been attributed to the chronic inflammation state caused by TNF-α. Accordingly, clinical trials to suppress TNF-α in ESRD patients have been conducted by several investigators [12-14]. On the contrary, TNF-α is known to have favorable and protective effects against infections [15-17], and in fact, TNF-α inhibition therapy has been associated with development of infections [18]. Then, what is the role of elevated TNF-α on the development of infection in ESRD patients? There is no answer to this question yet, but there is indirect evidence that TNF-α may lead to increased risk of infection: Girndt et al. [8] found that the potential of mononuclear cells to produce TNF-α correlated with non-responsiveness to hepatitis B vaccination in hemodialysis (HD) patients, suggesting the role of TNF-α in the immunosuppressive state in uremia. On the other hand, the production of TNF-α and IL-6 by mononuclear cells has been studied extensively in peritoneal dialysis (PD) patients, where PD fluids were found to impair the production of these cytokines by peritoneal macrophages or peripheral blood mononuclear cells (PBMCs) [19-25]. Since patients’ body fluids are repeatedly exposed to PD fluids, it is possible that PD fluids per se in addition to uremia may alter the function of mononuclear cells in circulation.
In the present study, we investigated the association of TNF-α and IL-6 with infection, the association of their plasma levels with their production by circulating mononuclear cells, and the association of TNF-α and IL-6 with various clinical parameters in PD patients.


Study subjects

We enrolled ESRD patients who had been on maintenance PD in the study, if they were 20 or older and did not have exclusion conditions including pregnancy, chronic viral infection (hepatitis and HIV), chronic inflammatory diseases, acute infection, or acute cardiovascular events. We also included healthy volunteers for controls who had no past medical history of chronic diseases and had not been on any medications. The study was approved by Ajou Institutional Review Board and written informed consent was obtained from the enrolled subjects.

Collection of blood samples and clinical data

Baseline characteristics of the patients were obtained from medical records. Blood samples for TNF-α and IL-6 were obtained at the start of the study when venipunctures were done for routine monthly blood tests, which included serum glucose, blood urea nitrogen, creatinine, albumin, cholesterol, white blood cell, and hematocrit. The data for C-reactive protein (CRP), Kt/V, and residual renal function (RRF) were obtained from medical records which had been done within 3 months of sample collection. Weekly Kt/Vurea was measured using a 24-hour collection of urine and a 24-hour collection of effluent for PD. RRF was calculated as the mean of creatinine clearance and urea clearance, normalized to the body surface area. Patients were followed up until death, loss to follow-up, switch to HD or transplantation, or study end.

Measurement of cytokines

Heparinized blood (10 mL) was collected to isolate plasma and PBMC. To isolate PBMC, blood was diluted with phosphate-buffered solution at 1 to 1 ratio, and then loaded on Ficoll-Paque gradient solutions (GE Healthcare Life Sciences, Little Chalfont, UK), centrifuged at 2,000 RPM for 30 minutes, and then mononuclear cell layers were collected. The isolated cells were suspended in RPMI 1640 media (Life Technologies, Waltham, MA, USA) supplemented with 10% fetal bovine serum and 0.05 mM 2-mercaptoethanol at the cell concentration of 1 × 106/mL. The cells were incubated with or without 100 ng/mL of lipopolysaccharide of Escherichia coli (serotype 055:B5, Sigma-Aldrich, St. Louis, MO, USA) for 24 hours at 37°C with 5% CO2, and culture media were centrifuged at 15,000 ×g for 5 minutes at 4°C. Plasma samples and culture media were analyzed for TNF-α and IL-6 protein concentrations by enzyme-linked immunosorbent assay (ELISA) using commercially available ELISA kits (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s specifications.

Statistical analysis

All Data were represented as mean ± SD. Characteristics of the patient groups were compared by Mann-Whitney tests and chi-square tests. Time to infection was tested using Kaplan-Meier survival anaysis and log rank test. Cox regression analysis was used to evaluate the effect of risk factors for infections. Pearson correlation analysis measured the strength of a relationship between two variables. A p value below 0.05 was considered statistically significant. SPSS version 22 (IBM Co., Armonk, NY, USA) was used for the statistical analysis.


Study participants and follow-up

Altogether, 32 PD patients and 10 healthy controls were enrolled in the study. All patients had been on PD for a mean of 2.7 years (range, 0.2 to 10.5). After sampling blood, they were followed for a mean duration of 775 days (range, 21 to 1,176). During the study period, two patients expired, seven received kidney transplants, four were changed to HD, and one transferred to another institution. Five patients developed pneumonia and one patient developed liver abscess, and these six patients were categorized as organ infections to distinguish them from PD related infections including peritonitis and exit site infection. Six patients developed PD peritonitis and eight developed exit site infection. Time to infection from blood sampling was 474.0 ± 405.2 days (range, 51 to 1,083) for organ infections, 1,689.8 ± 1,054.3 days for peritonitis (range, 815 to 2,835) and 334.7 ± 341.3 days (range, 28 to 992) for exit site infection. Sixteen patients were using combinations of bicarbonate/lactate buffered glucose solutions, amino acid solution and icodextrin solution and the others were on combinations of lactate buffered glucose solutions and icodextrin solutions.

Mean plasma cytokine levels and the development of infections

Plasma TNF-α levels were significantly elevated in patients with organ infections (n = 6) compared to those without infections (n = 26) or healthy controls (n = 10) (Fig. 1). However, plasma IL-6 levels were not significantly different between patients with organ infections versus those without infections (Fig. 1). Plasma TNF-α and IL-6 levels were not different in patients with peritonitis or exit site infection as compared with those without infections (Table 1).

Plasma cytokine as a predictor for infections

In univariate Cox regression analysis, plasma TNF-α and IL-6 levels were significant risk factors for organ infections, whereas other variables that are considered to have effect on infections such as diabetes, age, CRP (inflammation marker), serum albumin (nutritional marker), Kt/V (dialysis dose marker), and PD duration were not significant risk factors for organ infections (Table 2). Multivariate Cox regression analysis of plasma TNF-α together with IL-6 and the other covariates showed that plasma TNF-α was the only significant risk factor for organ infections (Table 2). The same analysis for pneumonia with the other covariates showed that plasma TNF-α was the only significant risk factor again (hazard ratio, 1.344; 95% confidence interval, 1.022 to 1.767; p = 0.034). In contrast, PD related infections including peritonitis and exit site infection were not associated with plasma TNF-α or IL-6 (data not shown).

Clinical outcomes by plasma cytokine levels

The cumulative hazard rate for organ infections was significantly greater in patients with high plasma TNF-α (top tertile defined by higher than 7.5 pg/mL) as compared with those with low TNF-α (bottom tertile defined by lower than 5.7 pg/mL), whereas it was similar in high (top tertile defined by higher than 8.0 pg/mL) and low plasma IL-6 (bottom tertile defined by lower than 5.8 pg/mL) groups (p = 0.174) (Fig. 2). Similarly, patients with high plasma TNF-α showed a significantly greater cumulative hazard rate for pneumonia (p = 0.044 by log rank test). Top and bottom TNF-α tertile groups were comparable in patient characteristics (Table 3). Plasma TNF-α or IL-6 levels did not show significant correlations with serum albumin, serum creatinine, and body mass index (BMI) which are considered as nutritional indicators (Table 4). Plasma TNF-α showed a significant correlation with IL-6 levels, and a significant inverse correlation with Kt/V but not with RRF (Table 4).

Cytokine production by PBMC in relation to plasma cytokine and infections

Pearson correlation analysis showed that plasma TNF-α and IL-6 levels were closely associated with the production by PBMC. Plasma TNF-α significantly correlated with unstimulated TNF-α production and showed a borderline significance with stimulated TNF-α production. The unstimulated TNF-α production inversely correlated with Kt/V but not with RRF (Table 5). Univariate Cox regression analysis showed that unstimulated and stimulated TNF-α production as well as unstimulated production of IL-6 were significant predictors of organ infection (Table 6).


In the present study, we found that elevated plasma TNF-α is a significant risk factor for organ infections especially pneumonia in PD patients, and to our knowledge, this is the first study demonstrating such association. Previous data showed that TNF-α causes loss of appetite and may lead to malnutrition in ESRD patients [1] and if it is the case, then malnutrition may be the reason for TNF-α induced infections. However, our study did not show correlations of plasma TNF-α with nutritional markers including serum albumin, serum creatinine, and BMI [26], which is consistent with the previous reports showing the irrelevance of TNF-α to the status of nutrition [10,27]. Accordingly, our study showed that serum albumin, a robust indicator of nutritional status [26], was not a significant risk factor for infections.
Though TNF-α is known to be a critical cytokine in defending host from infections, it has been shown that heightened TNF-α expression by PBMC is associated with defect in immune response in HD patients [8]. Our study advanced those findings by demonstrating that TNF-α expression by PBMC is actually a risk factor for infections as well as it correlates with plasma TNF-α levels. In fact, ours is the first study demonstrating the correlation between TNF-α expression by PBMC and plasma TNF-a levels, which indicates that an increased production may contribute to the elevation of circulating TNF-α levels in uremia. Given the protective role of TNF-α against infection, it can be hypothesized that TNF-α production is increased to compensate for uremia-induced immune compromised status predisposing to infections.
As for the role of dialysis dose on plasma TNF-α, our data showed that plasma TNF-α inversely correlated with Kt/V, suggesting that circulating TNF-α may be removed by PD, or plasma TNF-α production may be increased with a decrease in dialysis dose. Given the previous data showing that circulating cytokines with high molecular weights higher than 15 kDa are unlikely to be removed by peritoneal clearance [28], it is more likely that the production of TNF-α (molecular weight 17 kDa) may be increased in proportion to uremic toxins in blood, resulting in the inverse relationship between plasma TNF-α levels and Kt/V.
Our data showing that Kt/V inversely correlated with constitutive (unstimulated) TNF-α production by PBMC further suggest TNF-α production may be dependent on dialysis dose to some extent. RRF, which constitutes a part of Kt/V, did not correlate with plasma TNF-α, which may be due to a small amount of RRF of our patients not enough to affect plasma TNF-α levels.
In the present study, IL-6 was significantly elevated in PD patients and showed significant correlations with TNF-α; however, it did not show strong associations with organ infections as seen in TNF-α, suggesting a limited role of IL-6 in host immune status. Accordingly, it is hard to find data showing the association of IL-6 with immune competence in contrast to TNF-α which has been implicated in disturbances of host immune competence in many studies [8,15-18].
As for the mechanistic explanations for the observed link between TNF-α and organ infections, previous studies showed that TNF-α blocks IL-2 dependent clonal expansion of T cells [29] and that TNF-α produced by mononuclear cells induces non-responsiveness to hepatitis B vaccination [8], which indicate that TNF-α may have a suppressive effect on mounting an immune response against infection, resulting in increased susceptibility to infection. On the other hand, our data showed a lack of influence of circulating TNF-α on the rate of peritonitis, which suggests that the development of peritonitis may depend on the function of immune cells residing in peritoneal cavity rather than the function of circulating immune cells.
A limitation of this study is a small number of study subjects, which requires larger studies in the future to confirm the current findings. Another limitation is this study examined only a single measurement of cytokines. We believe that the current data would be strengthened by using the average of two or more samples or correlating the trend of multiple circulating cytokine levels with clinical outcomes.
In conclusion, we showed that plasma TNF-α is a risk factor for organ infections in PD patients. We also showed plasma TNF-α levels are associated with Kt/V and synthesis by PBMC. Further studies are required to verify our findings and develop measures to prevent infections in ESRD patients.


1. Plasma tumor necrosis factor α (TNF-α) is a risk factor for organ infections in peritoneal dialysis patients.
2. Plasma TNF-α levels are associated with Kt/V and synthesis by peripheral blood mononuclear cell.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

Figure 1.
Organ infections and plasma tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6) levels. ap = 0.000 vs. healthy controls, bp = 0.000 vs. healthy controls, cp = 0.000 vs. healthy controls and p = 0.017 vs. patients without infection, dp = 0.015 vs. healthy controls.
Figure 2.
Kaplan-Meier survival analysis of cumulative hazard rate for organ infections. (A) The line indicates data for patients with plasma tumor necrosis factor α (TNF-α) in the top tertile (> 7.5 pg/mL, n = 11) and in the bottom tertile (< 5.7 pg/mL, n = 12). The difference was significant at p = 0.009 by log rank test. (B) The line indicates data for patients with plasma interleukin 6 (IL-6) in the top tertile (> 8.0 pg/mL, n = 11) and in the bottom tertile (< 5.8 pg/mL, n = 11). The difference was not significant.
Table 1.
Plasma cytokine levels in peritoneal dialysis related infections
Infection type Control No infection Infection
Peritonitis 10 26 6
 TNF-α, pg/mL 3.1 ± 1.9 8.2 ± 4.3a 6.8 ± 1.7b
 IL-6, pg/mL 3.9 ± 0.6 9.8 ± 9.0a 6.5 ± 2.1c
Exit site infection 10 24 8
 TNF-α, pg/mL 3.1 ± 1.9 8.5 ± 4.4a 6.2 ± 1.8d
 IL-6, pg/mL 3.9 ± 0.6 9.8 ± 9.4a 7.3 ± 2.5b

Values are presented as mean ± SD.

TNF-α, tumor necrosis factor α; IL-6, interleukin 6.

a p = 0.000 vs. controls.

b p = 0.001 vs. controls.

c p = 0.008 vs. controls.

d p = 0.007 vs. controls.

Table 2.
Univariate and multivariate analysis for organ infections
Risk factor Univariate analysis
Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
Plasma TNF-α, pg/mL 1.392 (1.117–1.735) 0.003 1.701 (1.008–2.869) 0.046
Plasma IL-6, pg/mL 1.093 (1.021–1.170) 0.011 0.876 (0.663–1.158) 0.354
Diabetesa 4.688 (0.854–25.745) 0.075 3.926 (0.315–48.856) 0.288
Age, yr 1.022 (0.928–1.082) 0.957 0.969 (0.819–1.145) 0.710
CRP, mg/dL 1.666 (0.884–3.141) 0.115 3.093 (0.689–13.881) 0.141
Serum albumin, g/dL 0.313 (0.024–4.064) 0.375 1.356 (0.041–45.252) 0.865
Kt/V 0.120 (0.008–1.747) 0.121 1.332 (0.025–69.592) 0.887
PD duration, day 1.000 (0.999–1.001) 0.907 1.000 (0.999–1.002) 0.881

HR, hazard ratio; CI, confidence interval; TNF-α, tumor necrosis factor α; IL-6, interleukin 6; CRP, C-reactive protein; PD, peritoneal dialysis.

a Categorical value: p value below 0.05 is considered statistically significant.

Table 3.
Demographic characteristics by plasma tumor necrosis factor α tertiles
Characteristic Bottom (n = 12) Top (n = 11) p value
Age, yr 54.0 ± 9.8 52.1 ± 10.4 0.940
Female sex, %a 66.7 54.5 0.680
Diabetes, %a 33.3 45.5 0.680
C-reactive protein, mg/dL 0.7 ± 1.4 0.9 ±0.8 0.146
Glucose, mg/dL 128.9 ± 86.8 148.8 ± 59.3 0.091
White blood cell, /μL 7,633.3 ± 2,476.9 8,445.4 ± 2,347.4 0.404
Hematocrit, % 30.2 ± 3.7 29.2 ± 2.6 0.253
Blood urea nitrogen, mg/dL 60.2 ± 18.7 60.9 ± 15.3 0.845
Creatinine, mg/dL 10.1 ± 2.7 10.6 ± 2.9 0.576
Albumin, g/dL 3.8 ± 0.2 3.6 ± 0.4 0.493
Cholesterol, mg/dL 169.4 ± 32.1 155.0 ± 23.5 0.114
Body mass index, kg/m2 23.3 ± 3.0 24.2 ± 2.7 0.347
Kt/V 1.97 ± 0.36 1.74 ± 0.30 0.164
RRF, mL/min/1.73 m2 0.51 ± 0.45 0.26 ± 0.54 0.084
PD duration, day 1,647.0 ± 705.9 1,779.9 ± 715.0 0.651
LI regimen, %b 50.0 45.5 1.000

Values are presented as mean ± SD.

RRF, residual renal function; PD, peritoneal dialysis; LI, less intensive.

a Categorical values.

b LI regimen: combinations of lactate buffered-, and icodextrin solutions: p value below 0.05 is considered statistically significant.

Table 4.
Correlation matrix of cytokines and clinical parameters
Parameter pTNF-α pIL-6 Albumin Cr BMI Kt/V RRF Age
pIL-6 0.780a
Albumin –0.256 –0.318
Cr –0.140 –0.309 0.031
BMI 0.001 –0.266 0.411b 0.323
Kt/V –0.404b –0.438b 0.316 0.204 0.120
RRF –0.218 –0.211 0.181 –0.447b –0.156 –0.244
Age 0.030 0.094 0.259 –0.622a –0.280 –0.137 0.285
PD duration 0.034 –0.203 0.184 0.456a 0.250 0.137 –0.205 –0.208

The numbers shown are Pearson correlation coefficient (n = 32).

pTNF-α, plasma tumor necrosis factor α; pIL-6, plasma interleukin 6; BMI, body mass index; RRF, residual renal function; PD, peritoneal dialysis.

a Correlation is significant at the 0.01 level (2-tailed).

b Correlation is significant at the 0.05 level (2-tailed).

Table 5.
Correlation matrix of plasma and PBMC cytokines
Parameter pTNF-α pIL-6 Unst-TNF-α St-TNF-α Unst-IL-6 St-IL-6 Kt/V
pIL-6 0.780a
Unst-TNF-α 0.719a 0.733a
St-TNF-α 0.345c 0.258 0.286
Unst-IL-6 0.625a 0.265 0.306 0.161
St-IL-6 0.395b 0.440b –0.026 0.400b 0.182
Kt/V –0.404b –0.438b –0.374b –0.205 –0.119 –0.156
RRF –0.218 –0.211 –0.153 –0.141 –0.060 –0.151 –0.244

The numbers shown are Pearson correlation coefficient (n = 32).

pTNF-α, plasma tumor necrosis factor α; pIL-6, plasma interleukin 6; Unst-, unstimulated; St-, stimulated; RRF, residual renal function.

a Correlation is significant at the 0.01 level (2-tailed).

b Correlation is significant at the 0.05 level (2-tailed).

c p = 0.053.

Table 6.
Univariate analysis for organ infections
Risk factor HR (95% CI) p value
Unst-TNF-α, pg/mL 1.140 (1.039–1.252) 0.006
Unst-IL-6, pg/mL 1.040 (1.011–1.070) 0.006
St-TNF-α, pg/mL 1.001 (1.000–1.001) 0.009
St-IL-6, pg/mL 1.000 (1.000–1.000) 0.530

A p value below 0.05 is considered statistically significant.

HR, hazard ratio; CI, confidence interval; Unst-, unstimulated; TNF-α, tumor necrosis factor α; IL-6, interleukin 6; St-, stimulated.


1. Aguilera A, Codoceo R, Selgas R, et al. Anorexigen (TNF-alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: their relationship with nutritional parameters. Nephrol Dial Transplant 1998;13:1476–1483.
crossref pmid
2. Barreto DV, Barreto FC, Liabeuf S, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 2010;77:550–556.
crossref pmid
3. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005;16 Suppl 1:S83–S88.
crossref pmid
4. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002;17:1684–1688.
crossref pmid
5. Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998;32:107–114.
crossref pmid
6. Pecoits-Filho R, Heimburger O, Barany P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003;41:1212–1218.
crossref pmid
7. Bemelmans MH, Gouma DJ, Buurman WA. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 1993;150:2007–2017.
8. Girndt M, Kohler H, Schiedhelm-Weick E, Schlaak JF, Meyer zum Buschenfelde KH, Fleischer B. Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 1995;47:559–565.
crossref pmid
9. Girndt M, Sester U, Kaul H, Kohler H. Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. J Am Soc Nephrol 1998;9:1689–1696.
10. Canpolat N, Caliskan S, Sever L, et al. Malnutrition and its association with inflammation and vascular disease in children on maintenance dialysis. Pediatr Nephrol 2013;28:2149–2156.
crossref pmid
11. Kuragano T, Itoh K, Shimonaka Y, et al. Hepcidin as well as TNF-α are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol Dial Transplant 2011;26:2663–2667.
crossref pmid
12. Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol 2004;15:1877–1882.
crossref pmid
13. Goldstein SL, Leung JC, Silverstein DM. Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of aspirin. Clin J Am Soc Nephrol 2006;1:979–986.
crossref pmid
14. Gonzalez-Espinoza L, Rojas-Campos E, Medina-Perez M, Pena-Quintero P, Gomez-Navarro B, Cueto-Manzano AM. Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial. Nephrol Dial Transplant 2012;27:2023–2028.
crossref pmid
15. Echtenacher B, Mannel DN. Requirement of TNF and TNF receptor type 2 for LPS-induced protection from lethal septic peritonitis. J Endotoxin Res 2002;8:365–369.
crossref pmid
16. Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988;56:2563–2569.
crossref pmid pmc
17. van Dissel JT, van Langevelde P, Westendorp RG, Kwappenberg K, Frolich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998;351:950–953.
crossref pmid
18. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol Suppl 2002;65:33–38.
19. Cendoroglo M, Sundaram S, Jaber BL, Pereira BJ. Effect of glucose concentration, osmolality, and sterilization process of peritoneal dialysis fluids on cytokine production by peripheral blood mononuclear cells and polymorphonuclear cell functions in vitro. Am J Kidney Dis 1998;31:273–282.
crossref pmid
20. MacKenzie RK, Holmes CJ, Moseley A, et al. Bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFalpha secretion. J Am Soc Nephrol 1998;9:1499–1506.
21. Plum J, Schoenicke G, Grabensee B. Osmotic agents and buffers in peritoneal dialysis solution: monocyte cytokine release and in vitro cytotoxicity. Am J Kidney Dis 1997;30:413–422.
crossref pmid
22. Jorres A, Gahl GM, Ludat K, Frei U, Passlick-Deetjen J. In vitro biocompatibility evaluation of a novel bicarbonate-buffered amino-acid solution for peritoneal dialysis. Nephrol Dial Transplant 1997;12:543–549.
crossref pmid
23. Witowski J, Topley N, Jorres A, Liberek T, Coles GA, Williams JD. Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 1995;47:282–293.
crossref pmid
24. Rogachev B, Hausmann MJ, Yulzari R, et al. Effect of bicarbonate-based dialysis solutions on intracellular pH (pHi) and TNFalpha production by peritoneal macrophages. Perit Dial Int 1997;17:546–553.
25. Douvdevani A, Rapoport J, Konforti A, Zlotnik M, Chaimovitz C. The effect of peritoneal dialysis fluid on the release of IL-1 beta and TNF alpha by macrophages/monocytes. Perit Dial Int 1993;13:112–117.
26. Dwyer JT, Larive B, Leung J, et al. Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study? Kidney Int 2005;68:1766–1776.
crossref pmid
27. Beabaa N, Ozdemir S, Saatci U, et al. Nutritional assessment of children on haemodialysis: value of IGF-I, TNF-alpha and IL-1beta. Nephrol Dial Transplant 1998;13:1484–1488.
crossref pmid
28. Paniagua R, Ventura Mde J, Rodriguez E, et al. Impact of fill volume on peritoneal clearances and cytokine appearance in peritoneal dialysis. Perit Dial Int 2004;24:156–162.
29. Pawelec GP, Rehbein A, Schaudt K, Busch FW. IL-4-responsive human helper T cell clones are resistant to growth inhibition by tumor necrosis factor-alpha. J Immunol 1989;143:902–906.
Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6792   Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr
Copyright © 2020 The Korean Association of Internal Medicine. All rights reserved.
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
powerd by m2community